Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 6 od 100  
Back povratak na rezultate
2020, vol. 77, br. 12, str. 1309-1317
Ekspresija ziksina kod obolelih od nesitnoćelijskog karcinoma pluća
aSpecial Hospital for Lung Diseases "Ozren", Sokobanja
bUniversity of Niš, Faculty of Medicine, Department of Internal medicine, Niš
cUniverzitet u Nišu, Medicinski fakultet, Institut za biohemiju
dUniverzitet u Novom Sadu, Fakultet tehničkih nauka
eUniverzitet u Kragujevcu, Fakultet medicinskih nauka, Katedra za internu medicinu

e-adresadejan@soko-banja.org
Sažetak
Uvod/Cilj. Nesitnoćelijski karcinom pluća (engl. non-small cell lung cancer - NSCLC) je najčešći uzrok smrti od malignih tumora širom sveta. Rano otkrivanje bolesti najviše obećava u smislu smanjenja smrtnosti od ovog tipa karcinoma. Ziksin (ZYX) je član porodice proteina fokalnih adhezija, nedavno identifikovan kao potencijalni marker za rano otkrivanje NSCLC. Cilj studije bio je procena nivoa ekspresije ZYX kod obolelih od NSCLC i poređenje profila njegove ekspresije u serumu između ranih i odmaklih kliničkih stadijuma bolesti, različitih patohistoloških suptipova i različitih histoloških gradusa tumora. Metode. Uzorci krvi dobijeni su od 90 bolesnika sa verifikovanim NSCLC u svim kliničkim stadijumima bolesti i od 30 bolesnika bez kliničkih i radioloških znakova malignoma i bez prethodno verifikovane maligne bolesti. Za kvantitativno određivanje koncentracije humanog ZYX u krvi koristili smo ELISA (eng. enzyme-linked immunoadsorbent assay) test. Rezultati. Utvrđen je viši nivo ZYX u serumu bolesnika obolelih od NSCLC u poređenju sa kontrolnom grupom, sa izuzetno značajnom razlikom (p = 0,00). ROC kriva pokazala je visoku specifičnost testa sa AUC = 0,912. Nije bilo statistički značajne razlike u vrednostima ZYX kod dva najčešća tipa NSCLC, adenokarcinoma i skvamocelularnog karcinoma (p = 0,758). Nije utvrđena statistički značajna razlika u nivoima ZYX kod različitih kliničkih stadijuma bolesti (p = 0,518). Kod samo tri bolesnika verifikovan je dobro diferentovani tumor, pa nije bilo moguće izvući korisne podatke iz ovako malog uzorka. Nije utvrđena statistički značajna razlika u dobijenim vrednostima ZYX kod bolesnika sa srednje diferentovanim i loše diferentovanim tumorom (p = 0,48). Zaključak. Utvrdili smo da je ZYX prekomerno eksprimiran kod NSCLC, ali nivo ekspresije nije značajnije korelisao sa veličinom tumora, niti uznapredovalim tumor, node, metastasis (TNM) stadijumom bolesti. Naši rezultati sugerišu da serumski ZYX ima potencijal kao dijagnostički tumor marker za rano otkrivanje NSCLC, bez obzira da li se radi o adenokarcinomu ili skvamocelularnom karcinomu pluća.
Reference
Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., Fagerstrom, R.M., et al. (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5): 395-409
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics, 69(3): 89-95
Chassagnon, G., Revel, M.P. (2016) Dépistage du cancer du poumon: état des lieux et perspectives. Journal de Radiologie Diagnostique et Interventionnelle, 97(4): 369-374
Diepenbruck, M., Waldmeier, L., Ivanek, R., Berninger, P., Arnold, P., van Nimwegen, E., Christofori, G. (2014) Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. Journal of Cell Science, 127(Pt 7): 1523-1536
Duff, M.D., Mestre, J., Maddali, S., Yan, Z.P., Stapleton, P., Daly, J.M. (2007) Analysis of gene expression in the tumor-associated macrophage. Journal of Surgical Research, 142(1): 119-128
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A. (2010) AJCC cancer staging manual. New York: Springer, 7th ed
Grosjean, P., Ibanez, F. (2014) Pastecs: Package for Analysis of Space-Time Ecological Series. CRAN, https://cran.r-project.org/web/packages/pastecs/index.html [cited 2018 July 18]
Hirota, T., Morisaki, T., Nishiyama, Y., Marumoto, T., Tada, K., Hara, T., Masuko, N., Inagaki, M., Hatakeyama, K., Saya, H. (2000) Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. Journal of Cell Biology, 149(5): 1073-1086
Hoagland, L.F.M., Campa, M.J., Gottlin, E.B., Herndon, J.E., Patz, E.F. (2007) Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer, 110(10): 2260-2268
Kanoh, Y., Abe, T., Masuda, N., Akahoshi, T. (2013) Progression of non-small cell lung cancer: Diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncology Reports, 29(2): 469-473
Katki, H.A., Kovalchik, S.A., Berg, C.D., Cheung, L.C., Chaturvedi, A.K. (2016) Development and validation of risk models to select ever-smokers for CT lung-cancer screening. JAMA, 315(21): 2300-2311
Kawashima, Y., Fukutomi, T., Tomonaga, T., Takahashi, H., Nomura, F., Maeda, T., Kodera, Y. (2010) High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. Journal of Proteome Research, 9(4): 1694-1705
Kim, Y.J., Sertamo, K., Pierrard, M., Mesmin, C., Kim, S.Y., Schlesser, M., Berchem, G., Domon, B. (2015) Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. Journal of Proteome Research, 14(3): 1412-1419
Li, X., Asmitananda, T., Gao, L., Gai, D., Song, Z., Zhang, Y., Ren, H., Yang, T., Chen, T., Chen, M. (2012) Biomarkers in the lung cancer diagnosis: A clinical perspective. Neoplasma, 59(05): 500-507
Li, Y., Zhang, Y., Qiu, F., Qiu, Z. (2011) Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC. Electrophoresis, 32(15): 1976-1983
Ma, B., Cheng, H., Gao, R., Mu, C., Chen, L., Wu, S., Chen, Q., Zhu, Y. (2016) Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-b signalling pathways. Nature Communications, 7(1): 11123-11123
Mair, P., Schoenbrodt, F., Wilcox, R.R. (2017) WRS2: Wilcox robust estimation and testing. CRAN (English), https://cran.r-project.org/web/packages/WRS2/index.html [cited 2018 July 18]
Massion, P.P., Caprioli, R.M. (2006) Proteomic strategies for the characterization and the early detection of lung cancer. Journal of Thoracic Oncology, 1(9): 1027-1039
Mendeş, M., Akkartal, E. (2010) Comparison of ANOVA F and WELCH tests with their respective permutation versions in terms of type I error rates and test power. Kafkas Univ Vet Fak Derg, 16(5): 711-6
Mise, N., Savai, R., Yu, H., Schwarz, J., Kaminski, N., Eickelberg, O. (2012) Zyxin is a transforming growth factor-b (TGF-b)/Smad3 target gene that regulates lung cancer cell motility via integrin a5b1. Journal of Biological Chemistry, 287(37): 31393-31405
Rodríguez-Piñeiro, A.M., Blanco-Prieto, S., Sánchez-Otero, N., Rodríguez-Berrocal, F.J., de la Cadena, M. P. (2010) On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. Journal of Proteomics, 73(8): 1511-1522
Sawilowsky, S.S. (2009) New effect size rules of thumb. Journal of Modern Applied Statistical Methods, 8(2): 597-599
Siegel, R.L., Miller, K.D., Jemal, A. (2016) Cancer statistics: 2016. CA: A Cancer Journal for Clinicians, 66(1): 7-30
Smith, M.A., Blankman, E., Gardel, M.L., Luettjohann, L., Waterman, C.M., Beckerle, M.C. (2010) A zyxin-mediated mechanism for actin stress fiber maintenance and repair. Developmental Cell, 19(3): 365-376
Sun, N., Chen, Z., Tan, F., Zhang, B., Yao, R., Zhou, C., Li, J., Gao, Y., Liu, Z., Tan, X., Zhou, F., He, M.Y.F., Shao, K., Li, N., Qiu, B., Sun, J., Yu, Y., Wang, S., Zhao, Y., Shi, X., He, J. (2013) Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clinical Cancer Research, 19(18): 5136-5145
Sung, H., Ahn, J., Yoon, Y., Rhim, T., Park, C., Park, J., Lee, S., Kim, J., Cho, J. (2011) Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. Journal of Proteome Research, 10(3): 1383-1395
Sy, M.-H., Lai, P., Pang, E., Wong, L.-Y., To, K., Johnson, P.J., Wong, N.L. (2006) Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma. Modern Pathology, 19(8): 1108-1116
Torchiano, M. (2017) Effsize: Efficient Effect Size Computation. CRAN, https://cran.r-project.org/web/packages/effsize/index.html [cited 2018 July 18]
Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H.M., Beasley, M.B., et al. (2015) The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 10(9); 1243-60
Ulivi, P., Mercatali, L., Casoni, G., Scarpi, E., Bucchi, L., Silvestrini, R., Sanna, S., Monteverde, M., Amadori, D., Poletti, V., Zoli, W. (2013) Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One, 8(2): e57401-e57401
Wilcox, R.R. (2012) Introduction to robust estimation and hypothesis testing. Amsterdam-Boston: Academic Press
Wilcox, R.R., Tian, T.S. (2011) Measuring effect size: A robust heteroscedastic approach for two or more groups. Journal of Applied Statistics, 38(7): 1359-1368
Yang, J., Tan, D., Asch, H.L., Swede, H., Bepler, G., Geradts, J., Moysich, K.B. (2004) Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer, 46(1): 29-42
Yuen, K.K. (1974) The two-sample trimmed t for unequal population variances. Biometrika, 61(1): 165-170
Zhang, L., Chen, J., Ke, Y., Mansel, R.E., Jiang, W.G. (2006) Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. International Journal of Molecular Medicine, 17(5): 937-981
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP180810017I
primljen: 10.08.2018.
revidiran: 08.02.2019.
prihvaćen: 13.02.2019.
objavljen onlajn: 15.02.2019.
objavljen u SCIndeksu: 06.01.2021.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0